- Report
- October 2024
- 193 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
Bevantolol is a beta-blocker drug used to treat cardiovascular diseases such as hypertension, angina, and arrhythmias. It works by blocking the action of certain natural substances in the body, such as epinephrine, that affect the heart and blood vessels. Bevantolol is usually taken orally, but can also be administered intravenously. It is generally well tolerated, with few side effects.
Bevantolol is a widely used drug in the cardiovascular market, as it is effective in treating a variety of conditions. It is also relatively inexpensive, making it an attractive option for many patients. Additionally, it is available in both generic and brand-name formulations, allowing for greater access to the drug.
In the Bevantolol market, some of the major players include Pfizer, Merck, Novartis, and Sanofi. Other companies such as Mylan, Teva, and Sun Pharmaceuticals also have a presence in the market. Show Less Read more